The current therapeutic landscape remains constrained, with only two FDA-approved biologics, Benlysta and Saphnelo, available to manage the chronic autoimmune condition. While standard care continues to rely on glucocorticoids, the inherent toxicities of long-term steroid use have pushed pharmaceutical companies to prioritize disease-modifying agents that offer safer alternatives and improved patient outcomes.

Innovation is now split between oral small molecules and advanced cell therapies. Oral candidates like Cenerimod, Deucravacitinib, and Upadacitinib exemplify a shift toward multi-pathway immune modulation. Simultaneously, the emergence of CAR T-cell programs—including Rapcabtagene autoleucel and CABA-201—represents a potential leap toward one-time interventions that could induce durable, treatment-free remission in patients with refractory disease. While these cell therapies offer significant promise, they also introduce complex safety profiles, such as CRS and ICANS, necessitating rigorous clinical monitoring as they advance toward potential regulatory approval.